Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (222)	6/12/1998 2:26:00 AM
From: Czechsinthemail	Respond to of 399

John, It wasn't my intention to minimize the significance of the Wyeth-Ayerst collaboration. My question was more whether the stock might weaken upon the realization that it wasn't new business but a continuation of old business. I like ARQL and have been surprised at its stock weakness recently. regards, Baird

To: Dr. John M. de Castro who wrote (222)	6/16/1998 11:17:00 AM
From: StockDoc	Read Replies (1) \| Respond to of 399

You wrote: "... ARQL's profitability will occur when its molecules become drugs and are marketed. This is a clear indication that the development in this direction is going very well ..." I'm not clear on why this is good. Will this profitability be the standard time from discovery to market (usually 10 to 20 years)? Or do you have info on some specific compounds that could make it faster? Should not they just sell their early stage discoveries to big pharma or whoever to become profitable well before marketing those drugs? StockDoc